Home
Market News
Breaking stock market headlines
Earnings Flash
Breaking coverage of earnings reports, forecasts & dividend updates
Trends
Market movers, trading patterns & key market indicators
Disclosures
Official filings & reports from listed Japanese companies
Explorer
Stock lists filtered by fundamental & technical metrics
TSUBAKI NAKASHIMA, Last Fiscal Year's Net Income Unexpectedly Turns Profitable, The Current Fiscal Year's Net Income Turns to Loss, Falling into no Dividends
6464 TSUBAKI NAKASHIMA CO.,LTD. 【IFRS】
Earnings ReportTSUBAKI NAKASHIMA CO.,LTD. <6464> [TSE Prime] announced its financial results (based on IFRS) after the market closed on February 17th (20:30). The consolidated net income/loss for the fiscal year ending December 2024 turned into a profit of 0.91 billion yen (compared to a loss of 1.28 billion yen in the previous period), exceeding the forecast of a loss of 1.7 billion yen loss and turning an expected deficit into a profit. In the fiscal year ending December 2025, the loss is expected to turn into a loss of 0.8 billion yen.
At the same time, the company decided not to pay dividends this fiscal year (25 yen in the previous term).
In the most recent three-month period, from October to December (4Q), the consolidated net income/loss turned to a profit of 0.17 billion yen (compared to a loss of 2.47 billion yen in the same period last year). However, the operating profit/loss margin drastically worsened from 10.9% in the same period last year to -10.0%.
Kabutan News
Actual Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec, 2022 | 79,036 | -9,065 | -9,648 | -9,089 | -225.4 | 30 | Feb 20, 2023 | IFRS |
Dec, 2023 | 77,085 | 5,018 | 4,267 | -1,287 | -32.4 | 13 | Feb 9, 2024 | IFRS |
Dec, 2024 | 75,921 | 814 | 1,747 | 912 | 22.9 | 25 | Feb 17, 2025 | IFRS |
YoY | -1.5% | -83.8% | -59.1% | - | - |
Full Year Results vs. Previous Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec, 2024 Guidance | 75,000 | 500 | -900 | -1,700 | -42.7 | 25 | Nov 11, 2024 | IFRS |
Dec, 2024 Results | 75,921 | 814 | 1,747 | 912 | 22.9 | 25 | Feb 17, 2025 | IFRS |
Revision Rate | +1.2% | +62.8% | - | - | - |
Current Period Guidance
H1 Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Jan - Jun, 2024 | 40,304 | 2,170 | 2,764 | 1,703 | 42.8 | 15 | Aug 9, 2024 | IFRS |
Jan - Jun, 2025 Guidance | ー | ー | ー | ー | - | 0 | Feb 17, 2025 | IFRS |
YoY | - | - | - | - | - |
Current Period Guidance
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Adj. Dividend | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Dec, 2023 | 77,085 | 5,018 | 4,267 | -1,287 | -32.4 | 13 | Feb 9, 2024 | IFRS |
Dec, 2024 | 75,921 | 814 | 1,747 | 912 | 22.9 | 25 | Feb 17, 2025 | IFRS |
Dec, 2025 Guidance | 71,500 | 1,000 | -600 | -800 | -20.1 | 0 | Feb 17, 2025 | IFRS |
YoY | -5.8% | +22.9% | - | - | - |
Quarterly Results
Fiscal Year | Revenue | Operating Profit | Ordinary Profit | Net Profit | Adj. EPS | Operating Profit Margin | Announce | Accounting Standards |
---|---|---|---|---|---|---|---|---|
Oct - Dec, 2023 | 20,533 | 2,240 | 1,585 | -2,479 | -62.4 | 10.9 | Feb 9, 2024 | IFRS |
Jan - Mar, 2024 | 19,966 | 1,507 | 1,098 | 906 | 22.8 | 7.5 | May 13, 2024 | IFRS |
Apr - Jun, 2024 | 20,338 | 663 | 1,666 | 797 | 20.0 | 3.3 | Aug 9, 2024 | IFRS |
Jul - Sep, 2024 | 18,019 | 403 | -1,181 | -965 | -24.2 | 2.2 | Nov 11, 2024 | IFRS |
Oct - Dec, 2024 | 17,598 | -1,759 | 164 | 174 | 4.4 | -10.0 | Feb 17, 2025 | IFRS |
YoY | -14.3% | - | -89.7% | - | - |
Related Articles
Immuno-Biological Lab, The Current Fiscal Year Ordinary Profit Revised Upward to an Unexpected 44% Increase, Highest in Twenty Two Terms
ID Holdings, Current Fiscal Year Dividend Revised Upward by 12 yen
SYS Holdings, First Half Ordinary Profit Revised Upward to an Unexpected 7% Increase
Nikkei 225 open on the 18th = 13 yen higher, 39,187 yen
Nikkei 225 close on the 17th = rebound, 24 yen higher to 39,174 yen
MIRAI, The Current Fiscal Year Ordinary Profit Revised Upward to an Unexpected 3% Increase, Distribution Revised Upward by 90 yen
SRE Holdings, Current Fiscal Year Dividend Revised to 15 yen
CaSy, Announced business forecast for the fiscal year ending November 2025, Ordinary Profit to be break even
TOKYO KOKI, The Current Fiscal Year Ordinary Profit Revised Downward by 66%
SILVER LIFE, First Half Ordinary Profit Revised Upward by 22%